Literature DB >> 12147594

Substance P and its metabolites in normal human tears.

Masakazu Yamada1, Masaro Ogata, Masataka Kawai, Yukihiko Mashima, Teruo Nishida.   

Abstract

PURPOSE: To determine amounts and biochemical characteristics of substance P-like immunoreactivity (SPLI) in tears of normal human subjects.
METHODS: Forty-three healthy subjects (16 males and 27 females; age range, 17-80 years) participated. Ten microliters of unstimulated tears were collected with a micropipette from one eye of all subjects. Tear samples were partially purified by C-18 cartridges. SPLI concentrations in purified samples were measured by enzyme immunoassay (EIA). For biochemical characterization of SPLI, tear extracts were fractionated by high-performance liquid chromatography (HPLC). Each fraction then was subjected to EIA. To determine the metabolism of substance P in tears, synthetic substance P was incubated in medium containing pooled tears and then analyzed by HPLC with the detector set at a 210-nm wavelength.
RESULTS: The SPLI concentration in normal human tears was 306.0 +/- 96.5 pg/mL (mean +/- SD; range, 148-555 pg/mL). SPLI did not significantly vary by age or gender. HPLC analysis indicated that SPLI in tears consisted of five different substances and that substance P was converted to several fragments, including SP(8-11) by enzymes present in tears.
CONCLUSIONS: Substance P, a normal component of human tears, presumably is released from the nerve endings in the ocular surface and converted to fragments by degradative enzymes in tears.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147594

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiology.

Authors:  Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-18       Impact factor: 4.799

Review 2.  TFOS DEWS II pain and sensation report.

Authors:  Carlos Belmonte; Jason J Nichols; Stephanie M Cox; James A Brock; Carolyn G Begley; David A Bereiter; Darlene A Dartt; Anat Galor; Pedram Hamrah; Jason J Ivanusic; Deborah S Jacobs; Nancy A McNamara; Mark I Rosenblatt; Fiona Stapleton; James S Wolffsohn
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 3.  Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.

Authors:  Susmit Suvas
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

Review 4.  Immune regulation of the ocular surface.

Authors:  Yihe Chen; Shudan Wang; Hamid Alemi; Thomas Dohlman; Reza Dana
Journal:  Exp Eye Res       Date:  2022-03-04       Impact factor: 3.770

5.  Herpes zoster ophthalmicus.

Authors:  Srinivasan Sanjay; Philemon Huang; Raghavan Lavanya
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.972

Review 6.  Immunomodulatory Role of Neuropeptides in the Cornea.

Authors:  Sudan Puri; Brendan M Kenyon; Pedram Hamrah
Journal:  Biomedicines       Date:  2022-08-16

7.  Increasing substance P levels in serum and synovial tissues from patients with developmental dysplasia of the hip (DDH).

Authors:  Hui Wang; Xin-Feng Zheng; Xiang Zhang; Zheng Li; Chao Shen; Jun-Feng Zhu; Yi-Min Cui; Xiao-Dong Chen
Journal:  BMC Musculoskelet Disord       Date:  2014-03-19       Impact factor: 2.362

Review 8.  The Regenerative Potential of Substance P.

Authors:  Patrycja Redkiewicz
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.